RDHL — Redhill Biopharma Income Statement
0.000.00%
Last trade - 00:00- $4.01m
- $1.36m
- $8.04m
- 63
- 46
- 20
- 38
Annual income statement for Redhill Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 64.4 | 85.8 | 61.8 | 6.53 | 8.04 |
| Cost of Revenue | |||||
| Gross Profit | 28.3 | 45.3 | 28.5 | 3.07 | 4.85 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 128 | 167 | 105 | -26.7 | 22.7 |
| Operating Profit | -63.7 | -81.1 | -42.8 | 33.2 | -14.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -76.2 | -97.7 | -71.7 | 23.9 | -8.27 |
| Net Income After Taxes | -76.2 | -97.7 | -71.7 | 23.9 | -8.27 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -76.2 | -97.7 | -71.7 | 23.9 | -8.27 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -76.2 | -97.7 | -71.7 | 23.9 | -8.27 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.17 | -4.77 | -2.89 | 0.032 | -0.001 |